• Larimar Therapeutics held its annual shareholder meeting on May 19, 2026.
• Shareholders backed an amendment to the company’s certificate of incorporation to raise authorized common stock to 215,000,000 shares from 115,000,000.
• Investors also ratified PricewaterhouseCoopers as independent registered public accounting firm for fiscal 2026.
• Shareholders elected a one-year cadence for future advisory votes on executive pay, with the board set to hold those votes annually until the next required frequency vote.
• An adjournment authority was approved as a contingency to secure enough votes for the share authorization increase, though no adjournment was needed because the amendment passed at the meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-230852), on May 19, 2026, and is solely responsible for the information contained therein.